Short answer
ARS Pharmaceuticals, Inc. (SPRY) filed an 8-K current report with the SEC on May 15, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Fiscal quarter and full-year results ended March 31, 2026 announced.
ARS Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter and full-year results ended March 31, 2026 announced
- Exhibit 99.1 contains the financial results and accompanying management commentary
- Earnings release provides the primary investor detail for assessing operating performance and financial condition
Item 7.01 · Regulation FD Disclosure
- Updated investor presentation signals refreshed corporate messaging for analysts and shareholders
- Exhibit 99.2 contains the presentation, with potentially material strategy, product, or outlook updates
- Presentation available on the company website for investor review
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARS Pharmaceuticals, Inc. 8-K filings
Get the next SPRY 8-K as it lands
Follow SPRY for push alerts, or ask the research agent what this filing means.